Filing Flows › Rigel Pharmaceuticals (RIGL) › Q3 2026 › vs Q2 2026
Rigel Pharmaceuticals (RIGL) Q3 2026 vs Q2 2026 (quarter over quarter)
Rigel Pharmaceuticals's revenue rose $2.2M (+3%) from $78.7M in Q2 2026 to $80.9M in Q3 2026. The biggest changes: Product sales, net +$5.3M (+8%); Contract revenues from collaborations and other −$3.1M (-26%). Operating margin 21.1% against 30.0% (-8.8 pts).
Rigel Pharmaceuticals, Q3 2026: revenue $80.9M (+16% year over year), operating margin 21.1%, net earnings $13.2M, operating cash flow $34.6M. The chart draws each line against Q2 2026, the increases inside each band.
Margins
| Q3 2026 | Q2 2026 | Change | |
|---|---|---|---|
| Operating margin | 21.1% | 30.0% | -8.8 pts |
| Net margin | 16.3% | 22.0% | -5.7 pts |
Every line
| Line | Q3 2026 | Q2 2026 | Change | % |
|---|---|---|---|---|
| Product sales, net | $72.3M | $67.0M | $5.3M | +8% |
| Contract revenues from collaborations and other | $8.6M | $11.7M | −$3.1M | -26% |
| Revenue | $80.9M | $78.7M | $2.2M | +3% |
| Other income, net | $304K | $10K | $294K | 30× |
| Operating profit | $17.1M | $23.6M | −$6.5M | -27% |
| Costs & expenses | $63.8M | $55.1M | $8.7M | +16% |
| Pre-tax earnings | $17.4M | $23.6M | −$6.2M | -26% |
| Cost of revenue | $10.8M | $8.5M | $2.3M | +26% |
| Research & development | $18.3M | $14.0M | $4.3M | +31% |
| SG&A | $34.7M | $32.6M | $2.1M | +6% |
| Net earnings | $13.2M | $17.3M | −$4.1M | -24% |
| Income tax | $4.2M | $6.3M | −$2.1M | -33% |
| Depreciation & amortization | $1.8M | $848K | $945K | +111% |
| Share-based compensation | $4.9M | $6.8M | −$2.0M | -29% |
| Working capital & other | $14.7M | $5.7M | $9.1M | +160% |
| Operating cash flow | $34.6M | $30.7M | $3.9M | +13% |
Questions
How much did Rigel Pharmaceuticals's revenue grow quarter over quarter in Q3 2026?
Rigel Pharmaceuticals's revenue rose $2.2M (+3%) from $78.7M in Q2 2026 to $80.9M in Q3 2026.
What drove Rigel Pharmaceuticals's revenue change in Q3 2026?
Product sales, net +$5.3M (+8%); Contract revenues from collaborations and other −$3.1M (-26%).